CDK4 and cancer: The literature describes multiple mechanisms through which TGF-β may promote resistance to BRAFi/MEKi, EGFRi, HER2i, and CDK4/6i by activating alternative signaling routes, including proliferative and anti-apoptotic pathways across different cancer types [40,41,42,43,44,45,46].